首页|地诺孕素联合亮丙瑞林治疗子宫内膜异位症患者的疗效

地诺孕素联合亮丙瑞林治疗子宫内膜异位症患者的疗效

扫码查看
目的 探讨地诺孕素联合亮丙瑞林治疗子宫内膜异位症患者的疗效.方法 80例子宫内膜异位症患者随机分为观察组和对照组,每组40例.腹腔镜手术治疗后,对照组采用地诺孕素治疗,观察组采用地诺孕素联合亮丙瑞林治疗.比较两组患者VAS疼痛评分、临床疗效、卵巢储备功能、月经量、不良反应、包块体积和糖类抗原125(CA125)水平.结果 治疗3个月,两组患者非经期下腹痛评分、痛经评分及雌二醇、卵泡刺激素、CA125水平均低于治疗前(P<0.05),抗米勒管激素水平、窦卵泡计数和月经量评分均高于治疗前(P<0.05),包块体积小于治疗前(P<0.05).观察组的改善优于对照组(P<0.05).观察组治疗总有效率高于对照组(95.00%vs.77.50%)(P<0.05),不良反应发生率低于对照组(5.00%vs.30.00%)(P<0.05).结论 地诺孕素联合亮丙瑞林治疗子宫内膜异位症患者的疗效较好,可以缓解疼痛,恢复卵巢储备功能,改善月经紊乱,且不良反应少.
Efficacy of dienogest combined with leuprorelin in the treatment of patients with endometriosis
Objective To investigate the efficacy of dienogest combined with leuprorelin in the treatment of the patients with endometriosis.Methods Eighty patients with endometriosis were randomly divided into two groups with 40 cases each.After laparoscopic surgery treatment,group B was treated with dienogest,and group A was treated with dienogest combined with leuprorelin.The VAS pain score,clinical efficacy,ovarian reserve function,menstrual volume,adverse reactions,mass volume and CA125 level were compared between the two groups.Results After treated for 3 months,non-menstrual abdominal pain score,dysmenorrhea score and levels of estradiol,follicle stimulating hormone and CA125 were lower,anti-Müllerian hormone level,antral follicle counting and menstrual volume score were higher,and mass volume was smaller than those before,which were improved more obviously in group A than those in group B(P<0.05).The total effectiveness rate of group A was higher than that of group B(95.00%vs.77.50%)(P<0.05).The incidence of adverse reactions was lower in group A than that in group B(5.00%vs.30.00%)(P<0.05).Conclusion Dienogest combined with leuprorelin has better efficacy in the treatment of the patients with endometriosis,which can relieve pain,restore ovarian reserve function,improve menstrual disorders,and has fewer adverse reactions.

EndometriosisDienogestLeuprorelinOvarian reserve function

薛梦琪、曹蕾蕾、王治洁

展开 >

200235 上海市第八人民医院妇产科

子宫内膜异位症 地诺孕素 亮丙瑞林 卵巢储备功能

2024

江苏医药
江苏省人民医院(南京医科大学第一附属医院)

江苏医药

影响因子:0.707
ISSN:0253-3685
年,卷(期):2024.50(12)